APA (7th ed.) Citation

Papi, A., Greening, N. J., Bhatt, S. P., Roche, N., Celli, B., Wedzicha, J. A., . . . Ng, J. (2026). Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): Randomised, double-blind, placebo-controlled, phase 2b and 3 trials. Lancet, 407(10543), 2027. https://doi.org/10.1016/S0140-6736(26)00637-9

Chicago Style (17th ed.) Citation

Papi, Alberto, et al. "Safety and Efficacy of Astegolimab for COPD with Frequent Exacerbations Regardless of Baseline Blood Eosinophil Counts (ALIENTO and ARNASA): Randomised, Double-blind, Placebo-controlled, Phase 2b and 3 Trials." Lancet 407, no. 10543 (2026): 2027. https://doi.org/10.1016/S0140-6736(26)00637-9.

MLA (9th ed.) Citation

Papi, Alberto, et al. "Safety and Efficacy of Astegolimab for COPD with Frequent Exacerbations Regardless of Baseline Blood Eosinophil Counts (ALIENTO and ARNASA): Randomised, Double-blind, Placebo-controlled, Phase 2b and 3 Trials." Lancet, vol. 407, no. 10543, 2026, p. 2027, https://doi.org/10.1016/S0140-6736(26)00637-9.